Alzheimer’s Disease | Unmet Need | Mild to Moderate | US/EU | 2016
The need for improved AD therapeutics is considerable; current treatment options are limited, and none can cease or even delay the inexorable cognitive and functional decline caused by the disease. Mild to moderate AD is a key area of focus and commercial opportunity for the pharmaceutical industry: early-stage AD patients are the prime targets for disease-modifying interventions—the Holy Grail in AD drug development—and are also candidates for improved symptomatic options, which hinge on maximizing the function of existing neurons. New entrants that can safely deliver therapeutic gains over current mainstays are sought after by physicians, patients and their families, and healthcare systems that face a rapidly expanding AD population.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
